"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Novo Nordisk is the first manufacturer to market its drug Wegovy in pill form in the U.S., though Eli Lilly expects approval ...

People relying on popular weight-loss injections face rapid weight regain once treatment ceases, prompting recommendations ...

From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...

The convenience and lower cost of the oral pill may be critical to some patients, which could expand the market, improve ...

With weight loss drugs taking the world by storm, more people are exploring adding these medical marvels to their toolkits.

Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like ...

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk ...

Drugs like Ozempic have transformed how we treat obesity, but a review of almost 40 studies shows it doesn't take long for ...

A major study finds that weight loss drugs work while used, but weight and health benefits often return after stopping ...